Unraveling fibrosis by pharmacological targeting of the G protein-coupled receptor, RXFP1

通过药物靶向 G 蛋白偶联受体 RXFP1 来揭示纤维化

• 批准号: nhmrc : GNT1122170
• 负责人: A/Pr Chrishan Samuel
• 金额: $ 79.86万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/unraveling-fibrosis-pharmacological-receptor-rxfp1/1347251
• 关键词: Unraveling; fibrosis; pharmacological; targeting; protein

Peptides, with their high specificity and low toxicity profiles, are highly attractive alternatives to small molecule drugs. H2 relaxin, a peptide hormone, has a strong potential for treating fibrosis. However, the large size of H2 relaxin makes it difficult and expensive to manufacture. Once administered to patients, it is also quickly degraded. We have developed a small anti-fibrotic relaxin peptide, and propose to understand its mechanism of action and improve its therapeutic indices.

多肽具有高度的特异性和低毒特性，是小分子药物的极具吸引力的替代品。H2松弛素是一种多肽激素，具有很强的治疗纤维化的潜力。然而，H2松弛素的大尺寸使其制造困难且成本高昂。一旦给患者使用，它也会迅速降解。我们开发了一种小的抗纤维化松弛素肽，并建议了解其作用机制，提高其治疗指标。